リガンド・ファーマシューティカルズ【LGND】の掲示板
-
>>2
Gains complementary antibody technology and discovery lab, new revenue streams and four fully-funded partnerships with potential for milestones and royalties
Crystal is a leader in the difficult-to-address-epitope area of antibody research with its HuMab technology, which is believed to be the world’s only chicken-based human antibody platform to successfully generate human antibodies. As part of the OmniAb® brand, HuMab technology will be called OmniChicken™. Because of the evolutionary distance between birds and mammals, chickens enable the generation of novel antibodies against targets that are not immunogenic in mammals like mice and rats, the core species of Ligand’s existing OmniAb platform. The addition of the OmniChicken platform will be complementary to Ligand’s OmniAb technology, and further solidifies Ligand’s position as the world leader in novel, transgenic antibody discovery platforms.
kaz*ヒト投与可能で一斉摘発ｗ
ここが現在トリ抗体世界最強のCrystal Biosciencesを買収したとはビックリしたわｗ
もうトリ抗体応用は煮詰まって進捗が大分滞ってると思ってたからなｗ
それでも３０億弱の金額だからなｗ
LIV1205ADCの一本足打法のカイオムの時価総額は高すぎて異常ｗｗｗ
Ligand to Acquire Crystal Bioscience, the Leader in Chicken-derived Fully-human Antibody Generation, for $25 Million in Cash plus Additional Potential Payments
SAN DIEGO & EMERYVILLE, Calif.--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Crystal Bioscience, Inc. (Crystal) announce the signing of a merger agreement whereby Ligand will acquire Crystal, a leader in avian genetics and the generation of fully-human therapeutic antibodies. Under the terms of the agreement, Ligand will pay Crystal shareholders $25 million in cash at closing, up to an additional $10.5 million of success-based milestones, and revenue sharing from existing licensees for a defined period.